MEK抑制剂治疗的青少年多西环素预防。

IF 1.2 4区医学 Q3 DERMATOLOGY

Pediatric Dermatology Pub Date : 2025-05-28 DOI:10.1111/pde.15996

Faith Cormier, Irene Lara-Corrales, Rebecca Levy

{"title":"MEK抑制剂治疗的青少年多西环素预防。","authors":"Faith Cormier, Irene Lara-Corrales, Rebecca Levy","doi":"10.1111/pde.15996","DOIUrl":null,"url":null,"abstract":"Mitogen-activated protein kinase inhibitors (MEKi) are used to treat various conditions, including plexiform neurofibromas, brain tumors, and cancers. Our study aimed to determine whether doxycycline prophylaxis could reduce the frequency and/or severity of acneiform eruptions and paronychia, common side effects of MEKi. Our retrospective study included data from 43 patients aged 12 to 18 years, who received MEKi treatment at the Hospital for Sick Children, Toronto, Canada, between 2010 and 2023. We found that while doxycycline prophylaxis did not significantly impact the frequency or severity of acneiform eruptions (based on CTCAE grading), it appeared to be associated with fewer MEKi discontinuations due to skin toxicities and decreased rates of paronychia.","PeriodicalId":19819,"journal":{"name":"Pediatric Dermatology","volume":" ","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Doxycycline Prophylaxis in Adolescent Patients Treated With MEK Inhibitors.\",\"authors\":\"Faith Cormier, Irene Lara-Corrales, Rebecca Levy\",\"doi\":\"10.1111/pde.15996\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Mitogen-activated protein kinase inhibitors (MEKi) are used to treat various conditions, including plexiform neurofibromas, brain tumors, and cancers. Our study aimed to determine whether doxycycline prophylaxis could reduce the frequency and/or severity of acneiform eruptions and paronychia, common side effects of MEKi. Our retrospective study included data from 43 patients aged 12 to 18 years, who received MEKi treatment at the Hospital for Sick Children, Toronto, Canada, between 2010 and 2023. We found that while doxycycline prophylaxis did not significantly impact the frequency or severity of acneiform eruptions (based on CTCAE grading), it appeared to be associated with fewer MEKi discontinuations due to skin toxicities and decreased rates of paronychia.\",\"PeriodicalId\":19819,\"journal\":{\"name\":\"Pediatric Dermatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-05-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/pde.15996\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/pde.15996","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

丝裂原活化蛋白激酶抑制剂（MEKi）用于治疗各种疾病，包括丛状神经纤维瘤、脑肿瘤和癌症。我们的研究旨在确定多西环素预防是否可以减少痤疮样皮疹和甲沟炎的频率和/或严重程度，这是MEKi的常见副作用。我们的回顾性研究纳入了2010年至2023年期间在加拿大多伦多病童医院接受MEKi治疗的43名12至18岁患者的数据。我们发现，虽然多西环素预防对痤疮状爆发的频率或严重程度没有显著影响（基于CTCAE分级），但它似乎与因皮肤毒性导致的MEKi停药减少和甲沟炎发生率降低有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Doxycycline Prophylaxis in Adolescent Patients Treated With MEK Inhibitors.

Mitogen-activated protein kinase inhibitors (MEKi) are used to treat various conditions, including plexiform neurofibromas, brain tumors, and cancers. Our study aimed to determine whether doxycycline prophylaxis could reduce the frequency and/or severity of acneiform eruptions and paronychia, common side effects of MEKi. Our retrospective study included data from 43 patients aged 12 to 18 years, who received MEKi treatment at the Hospital for Sick Children, Toronto, Canada, between 2010 and 2023. We found that while doxycycline prophylaxis did not significantly impact the frequency or severity of acneiform eruptions (based on CTCAE grading), it appeared to be associated with fewer MEKi discontinuations due to skin toxicities and decreased rates of paronychia.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pediatric Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

6.70%

发文量

269

审稿时长

1 months

期刊介绍： Pediatric Dermatology answers the need for new ideas and strategies for today''s pediatrician or dermatologist. As a teaching vehicle, the Journal is still unsurpassed and it will continue to present the latest on topics such as hemangiomas, atopic dermatitis, rare and unusual presentations of childhood diseases, neonatal medicine, and therapeutic advances. As important progress is made in any area involving infants and children, Pediatric Dermatology is there to publish the findings.